Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it
The model's full reasoning — Q1 2024 call → NOWe need to determine if management describes an identifiable offering with both: (1) customer response running ahead of what company prepared for, and (2) company responding now by putting more behind it. The offering should be small relative to total business. Let's scan the transcript. Management discusses several products: NanoKnife, Auryon, mechanical thrombectomy (AngioVac, AlphaVac), Med Device (ports, Solero). Also PRESERVE study, APEX PE study. We need to find a specific offering where management says demand is exceeding what they prepared for, and they are taking concrete steps now to expand. Look for phrases like "ahead of", "exceeded", "more than we expected", "running ahead", "demand", "capacity", "staffing", "investment", "accelerating", "expanding". In the transcript, Jim Clemmer says: "Our NanoKnife business performed very well and grew approximately 36% during the first quarter, with sales of probes growing 35%. NanoKnife growth was strong again internationally, as our international team continues to establish new relationships with partners who assist in supporting our procedures and our strong U.S. growth was driven by continuing interest in this technology as more physicians become aware of our direct and preserved trials." That's just growth, not necessarily ahead of plan. Later: "We believe that NanoKnife has the potential to be one of the most important breakthroughs... It has the potential to open up a roughly $700 million market..." That's potential. For Auryon: "During the first quarter, we saw continued strong growth of our Auryon platform, up 26% year-over-year." No mention of exceeding preparation. For mechanical thrombectomy: "Our mechanical thrombectomy business, which includes AngioVac and AlphaVac declined roughly 6% year-over-year. We were encouraged to see that AngioVac revenues while down year-over-year, grew sequentially, and we believe that the steps we are taking to drive this business are gaining positive traction." That's not ahead. For AlphaVac: "Our APEX PE study is now more than 75% enrolled." That's a study, not an offering. For Med Device: "Growth in our Med Device segment was primarily driven by Ports and our Solero Microwave Ablation System. Our ports, which grew over 22%, illustrate the strength and leadership of our vascular access product portfolio and our commercial team.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).